Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents

Talamonti, Mark S.; Galluzzo, Marco

doi:10.1080/14712598.2021.1965985

Cited by 9 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a population-based cohort study by Pahalyants et al, immunomodulatory biologics are not associated with COVID-19 infection or subsequent mortality [ 74 ]. Several real-world studies have also demonstrated that biologics are safe for the management of patients with moderate to severe psoriasis who have been vaccinated against COVID-19 [ 22 , 75 ]. As of January 2022, approximately 12 billion vaccine doses have been administered, 140 vaccines have been developed in clinical trials, and a number of vaccines have reached approval for human use [ 76 ].…”

Section: Discussionmentioning

confidence: 99%

New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review

Huang

Wang

et al. 2022

Am J Clin Dermatol

View full text Add to dashboard Cite

Background Vaccination has been promoted to control viral transmission in response to the coronavirus disease 2019 (COVID-19) pandemic. Cases of new-onset or exacerbation of psoriasis, an immune-mediated inflammatory disease, were reported following COVID-19 vaccination. However, a comprehensive review examining the association between COVID-19 vaccination and the occurrence or exacerbation of psoriasis has yet to be performed. Objective The aim of this systematic review is to investigate the demographics, clinical variables, and outcomes associated with psoriasis following COVID-19 vaccination. Methods A systematic literature search was conducted using the PubMed, Embase, Web of Science, and Cochrane databases from database inception to April 25, 2022. The review included studies with relevant terms, including ‘psoriasis,’ ‘psoriasis vulgaris,’ ‘guttate psoriasis,’ ‘pustular psoriasis,’ ‘palmoplantar pustulosis,’ ‘psoriatic erythroderma,’ ‘psoriatic arthritis,’ ‘COVID-19,’ and ‘vaccine.’ We included all studies reporting at least one patient who developed new-onset psoriasis or experienced a psoriasis flare following at least one dose of any COVID-19 vaccine. A flare was defined as the worsening of disease conditions after vaccination according to the study by Gregoire et al. The appraisal tool described by Murad et al. was used to assess the quality of case reports and series, whereas the National Institute of Health quality assessment tool was used to assess observational studies. Results The initial search yielded 367 results, including 7 studies reporting new-onset psoriasis, 32 studies reporting psoriasis flares, and 4 studies reporting both. The most commonly observed psoriasis subtype was plaque-type psoriasis. mRNA vaccines, including those produced by Moderna and BioNTech/Pfizer, were frequently associated with subsequent psoriasis episodes. First, second, and third vaccine doses were associated with psoriasis incidents, with the second dose most frequently associated with psoriasis flares. Delayed onset was observed, ranging from 2 to 21 days in the new-onset group and from 1 to 90 days in the flare group. Most patients experienced favorable outcomes, with improvement or resolution occurring within 3 days to 4 months. Conclusions Both new-onset psoriasis and psoriasis flares were reported as cutaneous adverse events following COVID-19 vaccination. Psoriatic patients may require regular follow-up before and after COVID-19 vaccination. Trial Registration Review registration number PROSPERO database: CRD42022304157. Supplementary Information The online version contains supplementary material available at 10.1007/s40257-022-00721-z.

show abstract

Section: Discussionmentioning

confidence: 99%

New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review

Huang

Wang

et al. 2022

Am J Clin Dermatol

View full text Add to dashboard Cite

show abstract

“…Talamonti et al reported their real-life experience including 369 patients with moderate-to-severe psoriasis undergoing therapy with anti-IL (ani-IL12/23: 192; anti-IL17: 93; anti-IL23: 84). 60 None of these patients discontinued treatment during the study period (5 months). 60 No serious AEs were reported as well as about one-third of patients reported mild AEs seen in the general population (injection site pain, fever, fatigue, etc).…”

Section: Resultsmentioning

confidence: 98%

“… 60 None of these patients discontinued treatment during the study period (5 months). 60 No serious AEs were reported as well as about one-third of patients reported mild AEs seen in the general population (injection site pain, fever, fatigue, etc). 60 The safety of COVID-19 vaccines in psoriatic patients treated with biologics has been also investigated by Musumeci et al on a cohort of 50 patients with stable plaque psoriasis treated with biologics (anti-TNFα: 24; anti-IL17: 14; anti-IL12/23: 7: anti-IL23: 5) for at least 2 months who received COVID-19 vaccination.…”

Section: Resultsmentioning

confidence: 98%

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

Potestio¹,

Fabbrocini²,

Battista³

et al. 2023

PTT

View full text Add to dashboard Cite

The introduction of biologic drugs revolutionized the treatment of psoriasis, shifting treatment goals to higher treatment outcomes and less frequent safety issues. The outbreak of Coronavirus disease 2019 (COVID-19) represented a worldwide challenge, strongly affecting lifestyle, global economy, and overall health. Among the strategies adopted to contain the spreading of the infection, vaccination is the main one. In this context, the introduction of COVID-19 vaccines raised several doubts about their effectiveness and safety in patients undergoing therapy with biological for psoriasis. Even if molecular and cellular mechanisms by which COVID-19 vaccines lead to psoriasis development have not yet been fully elucidated, vaccination itself can trigger the release of interleukin (IL)-6, interferon (IFN) and tumor necrosis factor (TNF) α by T-helper (Th)1/Th17 cells. All these cytokines are involved in psoriasis pathogenesis. Thus, the aim of this manuscript is to review current literature on the safety and effectiveness of COVID-19 vaccination in psoriasis patients undergoing treatment with biologics, in order to clarify any concerns.

show abstract

“…It is known that vaccination against coronaviruses sometimes results in elevation of various cytokines [ 7 ]. We hypothesized that the coronavirus vaccine increased serum IL-6, which in turn increased serum ferritin levels, thereby creating an environment conducive to the development of fungal infections.…”

Section: Discussionmentioning

confidence: 99%

“…Although vaccination against coronaviruses in patients with psoriasis is safe, new onset or exacerbation of psoriasis after vaccination has been reported [ [7] , [8] , [9] ]. To the best of our knowledge, the exacerbation of tinea following coronavirus vaccination has not previously been reported.…”

Section: Introductionmentioning

confidence: 99%

A severe case of Trichophyton rubrum-caused dermatomycosis exacerbated after COVID-19 vaccination that had to be differentiated from pustular psoriasis

Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents

Cited by 9 publications

References 12 publications

New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review

New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

A severe case of Trichophyton rubrum-caused dermatomycosis exacerbated after COVID-19 vaccination that had to be differentiated from pustular psoriasis

Contact Info

Product

Resources

About